Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InnoCare PharmaINCPF 83 Interest Coverage is 22.33 as of Dec. 2025, which is 144% above its 10-year median of 9.16. GuruFocus rates INCPF with a GF Score™ of 83/100 and a GF Value™ of $2.32. The stock has 7 warning signs investors should review. Among 379 Biotechnology companies, InnoCare Pharma ranks worse than 77.04% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. InnoCare Pharma's
Operating Income
for the
six
months ended in Dec. 2025 was $85.3 Mil. InnoCare Pharma's Interest Expense for the
six
months ended in Dec. 2025 was $-3.8 Mil.
InnoCare Pharma's interest coverage for the quarter that ended in Dec. 2025 was 22.33.
The higher the ratio, the stronger the company's financial strength is.
The historical rank and industry rank for InnoCare Pharma's Interest Coverage or its related term are showing as below:
INCPF'
s Interest Coverage Range Over the Past 10 Years
Min: 9.16 Med: 9.16 Max: 9.23
Current: 9.23
INCPF's Interest Coverage is ranked worse than 77.04% of 379
companies
in the Biotechnology industry
Industry Median: 92.44
vs INCPF: 9.23
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
InnoCare Pharma Interest Coverage Related Terms
InnoCare Pharma Interest Coverage Historical Data
* Premium members only.
The historical data trend for InnoCare Pharma's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
INCPF vs VRTX, REGN, RVMD: Interest Coverage Comparison
For the Biotechnology subindustry, InnoCare Pharma's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InnoCare Pharma Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, InnoCare Pharma's Interest Coverage distribution charts can be found below:
* The bar in red indicates where InnoCare Pharma's Interest Coverage falls into.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InnoCare Pharma (INCPF) has a Interest Coverage of 22.33 as of Dec. 2025. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on InnoCare Pharma and its competitors. This is 144% above median its historical median of 9.16. Over the past decade, InnoCare Pharma's Interest Coverage has ranged from 9.16 to 9.23. According to the industry distribution chart, InnoCare Pharma ranks #292 out of 379 companies in the Biotechnology industry, placing it in the top 77%.
Is InnoCare Pharma's Interest Coverage too high?
InnoCare Pharma's current Interest Coverage of 22.33 is 144% above median its 10-year median of 9.16. Over the past 10 years, this metric has ranged from a low of 9.16 to a high of 9.23. The Biotechnology industry median Interest Coverage is 92.44. InnoCare Pharma's value of 22.33 is 75.8% below this industry median. Based on the distribution chart, InnoCare Pharma ranks #292 out of 379 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, InnoCare Pharma has a GF Score™ of 83/100, reflecting its overall financial health beyond just this single metric.
How does InnoCare Pharma's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, InnoCare Pharma ranks #292 out of 379 companies for Interest Coverage. This places InnoCare Pharma in the lower half of its industry. The industry median Interest Coverage is 92.44. InnoCare Pharma's value of 22.33 is 75.8% below this benchmark. Historically, InnoCare Pharma's own Interest Coverage has ranged from 9.16 to 9.23 over the past decade. While the company's 10-year median is 9.16 vs. the industry median of 92.44, InnoCare Pharma has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 92.44, based on 379 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. InnoCare Pharma's current Interest Coverage of 22.33 is 75.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on InnoCare Pharma and its competitors. For the Biotechnology industry, the median Interest Coverage is 92.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InnoCare Pharma's current Interest Coverage is 22.33, which is 144% above median its own 10-year median of 9.16. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InnoCare Pharma stock overvalued right now?
InnoCare Pharma (INCPF) has a current Interest Coverage of 22.33. The stock's GF Value™ is $2.32, compared to a current price of $1.55 — trading 33.2% below its estimated fair value. The current Interest Coverage is 22.33, which is 144% above median its 10-year median of 9.16 and 75.8% below the Biotechnology industry median of 92.44. InnoCare Pharma's overall GF Score™ is 83/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For InnoCare Pharma (INCPF), the current Interest Coverage is 22.33 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is InnoCare Pharma (INCPF) Overvalued in 2026?
Based on GuruFocus' analysis, InnoCare Pharma stock appears to be undervalued.
The current stock price of $1.55 is trading 33.2% below its estimated GF Value™ of $2.32.
Key valuation signals for INCPF:
Interest Coverage: 22.33 (144% above median its 10-year median of 9.16)
GF Value™: $2.32 vs. price of $1.55 (33.2% below fair value)
Industry Position: 75.8% below the Biotechnology median (#292 of 379)
No single metric tells the full story. See the INCPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.
83GF Score
Get the complete analysis for INCPF
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
INCPF has been successfully added to your 
